Mouse Recombinant Monoclonal IDH2 mutated R172S antibody. Suitable for WB, I-ELISA, ICC/IF and reacts with Recombinant fragment - Human, Human, Synthetic peptide - Human samples. Cited in 1 publication.
IgG1
Mouse
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
WB | I-ELISA | ICC/IF | |
---|---|---|---|
Human | Expected | Expected | Tested |
Recombinant fragment - Human | Tested | Not recommended | Not recommended |
Synthetic peptide - Human | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info 1.329 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info - | Notes Use at 1250ng/ml. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 26.58 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human, Synthetic peptide - Human | Dilution info - | Notes - |
Plays a role in intermediary metabolism and energy production. It may tightly associate or interact with the pyruvate dehydrogenase complex.
IDH, ICD-M, IDP, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, IDH2
Mouse Recombinant Monoclonal IDH2 mutated R172S antibody. Suitable for WB, I-ELISA, ICC/IF and reacts with Recombinant fragment - Human, Human, Synthetic peptide - Human samples. Cited in 1 publication.
IDH, ICD-M, IDP, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, IDH2
IgG1
Mouse
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
SMab-2
Affinity purification Protein A
kappa
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
This supplementary information is collated from multiple sources and compiled automatically.
Isocitrate dehydrogenase 2 (IDH2) is an enzyme that converts isocitrate to alpha-ketoglutarate in the citric acid cycle through oxidative decarboxylation. IDH2 also known as NADP-dependent isocitrate dehydrogenase has a molecular weight of about 51 kDa. This protein expresses in the mitochondria serving an important role in cellular energy production and intermediary metabolism. By facilitating this conversion IDH2 impacts cellular respiration and energy balance.
The IDH2 enzyme facilitates cellular metabolism by producing NADPH critical for biosynthesis and antioxidant defense. It functions within the oxidative decarboxylation of isocitrate providing reducing equivalents to keep cellular redox balance. Although not part of a larger enzymatic complex IDH2 acts synergistically with other metabolic enzymes to maintain cellular biochemical pathways.
The IDH2 protein participates in the citric acid cycle and redox homeostasis. IDH2 contributes to the tricarboxylic acid (TCA) pathway coupling with other TCA components such as citrate synthase and aconitase. Within the redox pathway it influences glucose metabolism via its link with enzymes like NADPH oxidase ensuring a steady supply of NADPH for biosynthetic reactions.
The IDH2 protein links to certain cancers like acute myeloid leukemia (AML) due to mutations such as IDH2 R140Q and IDH2 R172K which lead to the production of oncometabolite 2-hydroxyglutarate. This oncometabolite influences epigenetic regulation and cellular differentiation. IDH2 mutations often associate with altered tumor suppressor pathways involving proteins like TP53 contributing to tumorigenesis and impaired cellular differentiation.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Western blot - Anti-IDH2 (mutated R172 S) antibody [SMab-2] (ab264056).
The loading samples are E.coil extracts containing recombinant protein respectively.
ab264056 used at a 1/1000 dilution (1.329μg/ml), followed by Peroxidase-Conjugated Goat anti-Mouse IgG (H+L) secondary antibody at a 1/10,000 dilution.
Blocking/Dilution buffer: 5% NFDM/TBST.
Lane 1: His-tagged human IDH1 (aa1-414) recombinant protein 10ng
Lane 2: His-tagged human IDH1 mutated R132H (aa1-414) recombinant protein 10ng
Lane 3: His-tagged human IDH1 mutated R132G (aa1-414) recombinant protein 10ng
Lane 4: His-tagged human IDH1 mutated R132L (aa1-414) recombinant protein 10ng
Lane 5: His-tagged human IDH1 mutated R132S (aa1-414) recombinant protein 10ng
Lane 6: His-tagged human IDH1 mutated R132V (aa1-414) recombinant protein 10ng
Lane 7: His-tagged human IDH1 mutated R132C (aa1-414) recombinant protein 10ng
Lane 8: His-tagged human IDH2 (aa40-452) recombinant protein 10ng
Lane 9: His-tagged human IDH2 mutated R172M (aa40-452) recombinant protein 10ng
Lane 10: His-tagged human IDH2 mutated R172S (aa40-452) recombinant protein 10ng
Lane 11: His-tagged human IDH2 mutated R172G (aa40-452) recombinant protein 10ng
Lane 12: His-tagged human IDH2 mutated R172W (aa40-452) recombinant protein 10ng
Lane 13: His-tagged human IDH2 mutated R172K (aa40-452) recombinant protein 10ng
Lane 14: His-tagged human IDH2 mutated R140Q (aa40-452) recombinant protein 10ng
All lanes: Western blot - Anti-IDH2 (mutated R172S) antibody [SMab-2] (ab264056)
Predicted band size: 50 kDa
Exposure time: 3min
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized SW1353 (human chondrosarcoma cell line) cells labelling IDH2 (mutated R172 S) with ab264056 at 1/50 dilution (26.58μg/ml), followed by Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) ab150113 Goat Anti-mouse IgG H&L (Alexa Fluor® 488) antibody at 1/1000 dilution (Green). Confocal image showing cytoplasmic staining in SW1353 cells.
Negative control: HeLa (PMID: 25753205).
Anti-beta IV Tubulin antibody [EPR16775] ab179504 Anti-beta IV Tubulin antibody was used to counterstain tubulin at 1/200 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) ab150080 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) at a 1/1000 dilution (Red). The nuclear counterstain was DAPI (Blue).
Negative control 1: ab264056 at a 1/50 dilution (26.58μg/ml) followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) ab150080 at a 1/1000 dilution.
Negative control 2: Anti-beta IV Tubulin antibody [EPR16775] ab179504 at 1/200 dilution followed by Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) ab150113 at a 1/1000 dilution.
ELISA - Anti-IDH2 (mutated R172 S) antibody [SMab-2] (ab264056).
ab264056 used at 0-5000 ng/ml, followed by an Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Mouse IgG (H+L) secondary used at 1/1000 dilution.
Antigen concentration, 100 ng/ml.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com